Trial Outcomes & Findings for Effect of Whole-body Photobiomodulation on Muscular Performance Enhancement. (NCT NCT05989815)
NCT ID: NCT05989815
Last Updated: 2025-11-10
Results Overview
Mean serum creatine phosphokinase (CK) concentration (U/L), calculated as the average of four time points: Baseline, 24h, 48h, and 72h post-exercise. Higher values indicate greater muscle damage.
Recruitment status
COMPLETED
Study phase
NA
Target enrollment
30 participants
Primary outcome timeframe
Average of Baseline, 24h, 48h, and 72h
Results posted on
2025-11-10
Participant Flow
Participants with injuries that prevented them from practicing sports were excluded.
Participant milestones
| Measure |
PBMT Post Muscle Damage Protocol (PBMT-post)
Group submitted to pre-exercise Sham (placebo) photobiomodulation therapy (PBMT), and post-exercise active PBMT.
|
PBMT Pre (PBMT-pre)
Group submitted to pre-exercise active photobiomodulation therapy (PBMT), and post-exercise Sham (placebo) PBMT.
|
PBMT Placebo (PBMT-sham)
Group submitted to pre-exercise and post-exercise photobiomodulation therapy (PBMT) Sham (placebo).
|
|---|---|---|---|
|
Overall Study
STARTED
|
10
|
10
|
10
|
|
Overall Study
COMPLETED
|
10
|
10
|
10
|
|
Overall Study
NOT COMPLETED
|
0
|
0
|
0
|
Reasons for withdrawal
Withdrawal data not reported
Baseline Characteristics
Effect of Whole-body Photobiomodulation on Muscular Performance Enhancement.
Baseline characteristics by cohort
| Measure |
PBMT Post Muscle Damage Protocol (PBMT-post)
n=10 Participants
Group submitted to pre-exercise Sham (placebo) photobiomodulation therapy (PBMT), and post-exercise active PBMT.
|
PBMT Pre (PBMT-pre)
n=10 Participants
Group submitted to pre-exercise active photobiomodulation therapy (PBMT), and post-exercise Sham (placebo) PBMT.
|
PBMT Placebo (PBMT-sham)
n=10 Participants
Group submitted to pre-exercise and post-exercise photobiomodulation therapy (PBMT) Sham (placebo).
|
Total
n=30 Participants
Total of all reporting groups
|
|---|---|---|---|---|
|
Age, Categorical
<=18 years
|
0 Participants
n=5 Participants
|
0 Participants
n=20 Participants
|
0 Participants
n=40 Participants
|
0 Participants
n=28 Participants
|
|
Age, Categorical
Between 18 and 65 years
|
10 Participants
n=5 Participants
|
10 Participants
n=20 Participants
|
10 Participants
n=40 Participants
|
30 Participants
n=28 Participants
|
|
Age, Categorical
>=65 years
|
0 Participants
n=5 Participants
|
0 Participants
n=20 Participants
|
0 Participants
n=40 Participants
|
0 Participants
n=28 Participants
|
|
Age, Continuous
|
20 years
STANDARD_DEVIATION 1 • n=5 Participants
|
20 years
STANDARD_DEVIATION 1 • n=20 Participants
|
20 years
STANDARD_DEVIATION 1 • n=40 Participants
|
20 years
STANDARD_DEVIATION 1 • n=28 Participants
|
|
Sex: Female, Male
Female
|
0 Participants
n=5 Participants
|
0 Participants
n=20 Participants
|
0 Participants
n=40 Participants
|
0 Participants
n=28 Participants
|
|
Sex: Female, Male
Male
|
10 Participants
n=5 Participants
|
10 Participants
n=20 Participants
|
10 Participants
n=40 Participants
|
30 Participants
n=28 Participants
|
|
Race (NIH/OMB)
American Indian or Alaska Native
|
0 Participants
n=5 Participants
|
0 Participants
n=20 Participants
|
0 Participants
n=40 Participants
|
0 Participants
n=28 Participants
|
|
Race (NIH/OMB)
Asian
|
0 Participants
n=5 Participants
|
0 Participants
n=20 Participants
|
0 Participants
n=40 Participants
|
0 Participants
n=28 Participants
|
|
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
|
0 Participants
n=5 Participants
|
0 Participants
n=20 Participants
|
0 Participants
n=40 Participants
|
0 Participants
n=28 Participants
|
|
Race (NIH/OMB)
Black or African American
|
0 Participants
n=5 Participants
|
0 Participants
n=20 Participants
|
0 Participants
n=40 Participants
|
0 Participants
n=28 Participants
|
|
Race (NIH/OMB)
White
|
0 Participants
n=5 Participants
|
0 Participants
n=20 Participants
|
0 Participants
n=40 Participants
|
0 Participants
n=28 Participants
|
|
Race (NIH/OMB)
More than one race
|
10 Participants
n=5 Participants
|
10 Participants
n=20 Participants
|
10 Participants
n=40 Participants
|
30 Participants
n=28 Participants
|
|
Race (NIH/OMB)
Unknown or Not Reported
|
0 Participants
n=5 Participants
|
0 Participants
n=20 Participants
|
0 Participants
n=40 Participants
|
0 Participants
n=28 Participants
|
|
Region of Enrollment
Brazil
|
10 participants
n=5 Participants
|
10 participants
n=20 Participants
|
10 participants
n=40 Participants
|
30 participants
n=28 Participants
|
PRIMARY outcome
Timeframe: Average of Baseline, 24h, 48h, and 72hMean serum creatine phosphokinase (CK) concentration (U/L), calculated as the average of four time points: Baseline, 24h, 48h, and 72h post-exercise. Higher values indicate greater muscle damage.
Outcome measures
| Measure |
PBMT Pre (PBMT-pre)
n=10 Participants
Group submitted to pre-exercise active photobiomodulation therapy (PBMT), and post-exercise Sham (placebo) PBMT.
|
PBMT Placebo (PBMT-sham)
n=10 Participants
Group submitted to pre-exercise and post-exercise photobiomodulation therapy (PBMT) Sham (placebo).
|
PBMT Post Muscle Damage Protocol (PBMT-post)
n=10 Participants
Group submitted to pre-exercise Sham (placebo) photobiomodulation therapy (PBMT), and post-exercise active PBMT.
|
|---|---|---|---|
|
Measurement of Blood Levels of Creatine Phosphokinase (CK)
|
249.2 U/L
Standard Deviation 112.28
|
289.2 U/L
Standard Deviation 209.94
|
287.8 U/L
Standard Deviation 199.09
|
SECONDARY outcome
Timeframe: Average of Baseline, 24h, 48h, 72hVertical jump height (cm) measured by the Squat Jump (SJ) test. Mean of four time points: Baseline, 24h, 48h, and 72h after the protocol. Higher values indicate better performance.
Outcome measures
| Measure |
PBMT Pre (PBMT-pre)
n=10 Participants
Group submitted to pre-exercise active photobiomodulation therapy (PBMT), and post-exercise Sham (placebo) PBMT.
|
PBMT Placebo (PBMT-sham)
n=10 Participants
Group submitted to pre-exercise and post-exercise photobiomodulation therapy (PBMT) Sham (placebo).
|
PBMT Post Muscle Damage Protocol (PBMT-post)
n=10 Participants
Group submitted to pre-exercise Sham (placebo) photobiomodulation therapy (PBMT), and post-exercise active PBMT.
|
|---|---|---|---|
|
Squat Jump (SJ) Height
|
38.91 cm
Standard Deviation 5.45
|
38.56 cm
Standard Deviation 4.09
|
37.38 cm
Standard Deviation 5.22
|
SECONDARY outcome
Timeframe: Average of Baseline, 24h, 48h, and 72hPeak isometric force (kgf) of knee extensors, measured with handheld dynamometry. Mean of Baseline, 24h, 48h, and 72h after exercise. Higher values indicate better performance.
Outcome measures
| Measure |
PBMT Pre (PBMT-pre)
n=10 Participants
Group submitted to pre-exercise active photobiomodulation therapy (PBMT), and post-exercise Sham (placebo) PBMT.
|
PBMT Placebo (PBMT-sham)
n=10 Participants
Group submitted to pre-exercise and post-exercise photobiomodulation therapy (PBMT) Sham (placebo).
|
PBMT Post Muscle Damage Protocol (PBMT-post)
n=10 Participants
Group submitted to pre-exercise Sham (placebo) photobiomodulation therapy (PBMT), and post-exercise active PBMT.
|
|---|---|---|---|
|
Muscle Performance Tests - Dynamometry
|
53.45 kgf (kilogram-force)
Standard Deviation 8.63
|
55.58 kgf (kilogram-force)
Standard Deviation 10.45
|
59.19 kgf (kilogram-force)
Standard Deviation 8.34
|
SECONDARY outcome
Timeframe: Average of Baseline, 24h, 48h, and 72hDOMS intensity assessed using a Numeric Rating Scale (NRS; 0-10), where 0 = no soreness and 10 = worst possible soreness during knee extension. Higher scores indicate greater soreness. Mean of Baseline, 24h, 48h, and 72h post-protocol.
Outcome measures
| Measure |
PBMT Pre (PBMT-pre)
n=10 Participants
Group submitted to pre-exercise active photobiomodulation therapy (PBMT), and post-exercise Sham (placebo) PBMT.
|
PBMT Placebo (PBMT-sham)
n=10 Participants
Group submitted to pre-exercise and post-exercise photobiomodulation therapy (PBMT) Sham (placebo).
|
PBMT Post Muscle Damage Protocol (PBMT-post)
n=10 Participants
Group submitted to pre-exercise Sham (placebo) photobiomodulation therapy (PBMT), and post-exercise active PBMT.
|
|---|---|---|---|
|
Delayed Onset Muscle Soreness (DOMS)
|
3.80 points on NRS (0-10)
Standard Deviation 2.74
|
5.70 points on NRS (0-10)
Standard Deviation 2.05
|
3.00 points on NRS (0-10)
Standard Deviation 2.00
|
SECONDARY outcome
Timeframe: Average of Baseline, 24h, 48h, 72hVertical jump height (cm) measured by the Countermovement Jump (CMJ) test. Mean of four time points: Baseline, 24h, 48h, and 72h after the protocol. Higher values indicate better performance.
Outcome measures
| Measure |
PBMT Pre (PBMT-pre)
n=10 Participants
Group submitted to pre-exercise active photobiomodulation therapy (PBMT), and post-exercise Sham (placebo) PBMT.
|
PBMT Placebo (PBMT-sham)
n=10 Participants
Group submitted to pre-exercise and post-exercise photobiomodulation therapy (PBMT) Sham (placebo).
|
PBMT Post Muscle Damage Protocol (PBMT-post)
n=10 Participants
Group submitted to pre-exercise Sham (placebo) photobiomodulation therapy (PBMT), and post-exercise active PBMT.
|
|---|---|---|---|
|
Countermovement Jump (CMJ) Height
|
41.56 cm
Standard Deviation 6.73
|
40.55 cm
Standard Deviation 4.28
|
39.36 cm
Standard Deviation 4.27
|
Adverse Events
PBMT Post Muscle Damage Protocol (PBMT-post)
Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths
PBMT Pre (PBMT-pre)
Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths
PBMT Placebo (PBMT-sham)
Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths
Serious adverse events
Adverse event data not reported
Other adverse events
Adverse event data not reported
Additional Information
Italo Amaral de Oliveira, Principal Investigator
Federal University of São Carlos (UFSCar)
Phone: +55 19 99719-0361
Email: [email protected]
Results disclosure agreements
- Principal investigator is a sponsor employee
- Publication restrictions are in place